Urapidil: an unknown / known antihypertensive
Authors:
Jiří Slíva
Authors‘ workplace:
Ústav farmakologie, 3. LF UK, Praha
Published in:
Vnitř Lék 2022; 68(4): 253-256
Category:
Overview
Essential arterial hypertension is not a disease that would significantly adversely affect patients in their daily activities. At least mostly. Nonetheless, it has a significant negative impact on cardiovascular morbidity and mortality. The tight correlation with the degree of hypertension, the patient’s age and, of course, commorbidities and cardiovascular risk factors is obvious. Therefore, the goal of hypertensive therapy is not only to try to achieve optimal reduction of blood pressure, but in a broader sense to reduce the risk of the just mentioned consequences, i.e. to reduce morbidity and reduce mortality. The antihypertensive drug urapidil can also be used in pharmacotherapy, the brief description of which is the subject of this article.
Keywords:
hypertension – treatment – urapidil – antihypertensives
Sources
1. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur.Heart J 2018; 39: 3021-3104.
2. Buch J. Urapidil, a dual‑acting antihypertensive agent: Current usage considerations. Adv Ther 2010;27:426-443.
3. Langtry HD, Mammen GJ, Sorkin EM. Urapidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs 1989;38:900-940.
4. Dooley M, Goa KL. Urapidil. A reappraisal of its use in the management of hypertension. Drugs 1998;56:929-955.
5. Fariello R, Dal PC, Pessina A et al. Antihypertensive efficacy of urapidil versus hydrochlorothiazide alone in patients with mild to moderate essential hypertension and of their combination in nonresponders to monotherapy. Drugs 1990;40 Suppl 4:60-62.
6. SPC. Ebrantil retard 30 mg tvrdé tobolky s prodlouženým uvolňováním. Zdroj: www. sukl.cz (posl. přístup 22/01/2022).
7. Kirsten R, Nelson K, Steinijans VW, Zech K, Haerlin R. Clinical pharmacokinetics of urapidil. Clin Pharmacokinet. 1988 Mar;14(3):129-40.
8. Gerber A, Weidmann P, Marone C et al. Cardiovascular and metabolic profile during intervention with urapidil in humans. Hypertension 1985;7:963-971.
9. Haerlin R, Engelstratter R, Henze F, Radtke HW. Treatment of primary and secondary hypertension. Long‑term use of urapidil (Ebrantil‘P). Clinic al Trials Journal. Clinic al Trials Journal 1985;22:215-223.
10. Trimarco B, Rosiello G, Feldhaus P et al. Efficacy of once‑daily urapidil treatment in mild or moderate essential hypertension assessed by ambulatory 24-hour blood pressure monitoring. Drugs. 1988;35 Suppl 6:173-181.
11. Zanchetti A. Addition of urapidil or metoprolol to the treatment of hypertensive non‑responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Blood Press Suppl 1995;3:38-46.
12. Hansson L, Petitet A. Review of studies with urapidil in elderly hypertensives. Blood Press Suppl. 1995;3:21-5.
13. Alijotas‑Reig J, Bove‑ Farre I, de Cabo‑ Frances F, Angles‑Coll R. Effectiveness and safety of prehospital urapidil for hypertensive emergencies. Am J Emerg.Med 2001;19:130-133.
14. Cherney D, Straus S. Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature. J Gen Intern Med. 2002 Dec;17(12):937-45.
15. Souček M, Novák J. Urapidil v léčbě hypertenzní krize Interv Akut Kardiol 2013;12(3):150- 152.
16. Yang W, Zhou YJ, Fu Y et al. Therapeutic effects of intravenous urapidil in elderly patients with hypertension and acute decompensated heart failure: A pilot clinical trial. Exp. Ther Med 2016;12:115-122.
17. Yang W, Zhou YJ, Fu Y et al. Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial. Yonsei Med J 2017;58:105-113.
18. Shi J, Li Y, Xing C et al. Urapidil, compared to nitroglycerin, has better clinical safety in the treatment of hypertensive patients with acute heart failure: a meta‑analysis. Drug Des Devel.Ther 2019;13:161-172.
19. Carles G, Helou J, Dallah F et al. Utilisation de l‘urapidil injectable dans l‘hypertension gravidique et la prééclampsie (Use of injectable urapidil in pregnancy‑induced hypertension and preeclampsia). J Gynecol Obstet Biol Reprod (Paris). 2012 Nov;41(7):645-649.
20. Wacker JR, Wagner BK, Briese V et al. Antihypertensive therapy in patients with pre‑eclampsia: A prospective randomised multicentre study comparing dihydralazine with urapidil. Eur J Obstet Gynecol Reprod Biol. 2006 Aug;127(2):160-165.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2022 Issue 4
Most read in this issue
- Development of recommendations for the use of venoactive drugs in the treatment of chronic venous disease – where they are effective and where they are not
- Acetylsalicylic acid in primary prevention of cardiovascular disease
- COVID-19 and post-COVID – Jekyll and Hyde of modern medicine
- Acute kidney injury due to antimicrobial therapy